

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC.,
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2024-00631
Patent 10,335,462

DECLARATION OF SAYEM OSMAN

I, Sayem Osman, make the following Declaration pursuant to 28 U.S.C. § 1746:

1. I am a paralegal at the law firm of Groombridge, Wu, Baughman & Stone LLP.
2. I provide this Declaration in connection with the above-identified Patent Owner's Preliminary Response to the *Inter Partes* Review proceeding that is being requested at the U.S. Patent and Trademark Office by Petitioners under 35 U.S.C. §§ 311-319, 37 C.F.R. § 42. Unless otherwise stated, the facts stated in this Declaration are based on my personal knowledge.
3. EX2001 hereto is a true and correct copy of the docket, *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website (<https://ptacts.uspto.gov/ptacts/ui/case-viewer/15656042/IPR2023-00724/aia-review-info>). An exhibit label and page numbers to the bottom of all pages of EX2001, no other alterations have been made.
4. EX2002 hereto is a true and correct copy of the Joint Stipulation to Modify Due Dates 2, 3, 4, 5, 6, 7 and 8, *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724 Paper 47, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website (<https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=ZSwtZzaGppMNsiuUNZa1KO9FV3yeSKMhq2rlSRP2K9Fg>

[CXUAv1bIZ7Y](#)). An exhibit label and page numbers have been added to the bottom of all pages of EX2002 but no other alterations have been made.

5. EX2003 hereto is a true and correct copy of the June 7, 2024 Joint Stipulation to Modify Due Dates 3, 4, 5, 6, 7 and 8, *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, Paper 56, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website

([https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-](https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=NhfE33Inpj9yzzKYI8BeFXsmuCC-)

[documents?artifactId=NhfE33Inpj9yzzKYI8BeFXsmuCC-kwuIjJbHcqznjUj3VPnPzfvFRSI](#)). An exhibit label and page numbers have been added to the bottom of all pages of EX2003 but no other alterations have been made.

6. EX2004 hereto is a true and correct copy of an excerpt of Patent Owner's Response, *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, Paper 30, which I retrieved on June 11, 2024, from the United States Patent & Trademark

Office's P-TACTS website ([https://ptacts.uspto.gov/ptacts/public-](https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-)

[documents?artifactId=CjJP0SzQ0sIADDecOlxim2c2CqGfLhSxw99Gsb6hUyspd5zx-ryK44Q](#)). Other than excerpting the pages, striking through the protective order

material designation and adding an exhibit label and page numbers to the bottom of all pages of EX2004, no other alterations have been made.

7. EX2005 hereto is a true and correct copy of an excerpt of the Declaration of George L. Bakris, M.D., *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, EX2011, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website (https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=-FCkEpnagGvffhCalbzEm3F6SYFxYLFJ71HWJ4yM2REkZ_prIDFtjig). Other than excerpting the pages and adding an exhibit label and page numbers to the bottom of all pages of EX2005, no other alterations have been made.

8. EX2006 hereto is a true and correct copy of an excerpt of the Declaration of Robin S. Goland, M.D., *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, EX2054, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website (https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=-JRuzDuWIHuFcCmlYfPHwj1_jqHrD9V6ID7g5WhGMz1GMAF6DtBwmmY).

Other than excerpting the pages and adding an exhibit label and page numbers to the bottom of all pages of EX2006, no other alterations have been made.

9. EX2007 hereto is a true and correct copy of an excerpt of the Declaration of Michael J. Blaha, M.D., *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, EX2055, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website (<https://ptacts.uspto.gov/ptacts/public->

[https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=u5E3-wHgf-](https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=u5E3-wHgf-6JpUOGXhJ6PVOKnpDlpejA9szbFn4fx7p1sa3qqUqKBFI)

[6JpUOGXhJ6PVOKnpDlpejA9szbFn4fx7p1sa3qqUqKBFI](https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=u5E3-wHgf-6JpUOGXhJ6PVOKnpDlpejA9szbFn4fx7p1sa3qqUqKBFI)). Other than excerpting the pages and adding an exhibit label and page numbers to the bottom of all pages of EX2007, no other alterations have been made.

10. EX2008 hereto is a true and correct copy of an excerpt of the Declaration of Christopher A. Vellturo, Ph.D., *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, EX2300, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website (<https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=YaU8ZpbeHQJvc5HYDIcU6FaJLXWnsBC9GpSuYYWYT wYj3LS6w0Hctps>). Other than excerpting the pages, striking through the protective order material designation and adding an exhibit label and page numbers to the bottom of all pages of EX2008, no other alterations have been made.

11. EX2009 hereto is a true and correct copy of an excerpt of the Declaration of Patrick J. Sinko, Ph.D., *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, EX2056, which I retrieved on June 11, 2024, from the United States Patent & Trademark Office's P-TACTS website (<https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=OhRjgPO32RkdKD0ezICGBI5EaOzYR8V30lZiSMadEi2hcAiaejnkdlg>). Other than excerpting the pages, striking through the protective order

material designation and adding an exhibit label and page numbers to the bottom of all pages of EX2009, no other alterations have been made.

12. EX2010 hereto is a true and correct copy of an email from Counsel for Petitioner re IPR2024-00631. I received this email on June 10, 2024 as a member of an email distribution group. An exhibit label and page numbers have been added to the bottom of all pages of EX2010 but no other alterations have been made.

13. EX2011 hereto is a true and correct copy of Ozempic's Orange Book, *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, which I retrieved on June 11, 2024, from

https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=209637&Appl_type=N. An exhibit label and page numbers have been added to the bottom of all pages of EX2011 but no other alterations have been made.

14. I have been warned that willful false statements and the like are punishable by fine or imprisonment, or both. I make this declaration of my own personal knowledge, and all statements are true. If called to testify as to the truth of the matters stated herein, I could and would testify competently.

15. I declare under penalty of perjury that the foregoing is true and correct.

Executed on this 12th day of June, 2024, at Washington, D.C.

/Sayem Osman/
Sayem Osman